Northeast Financial Consultants’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.69M | Hold |
6,040
| – | – | 0.11% | 90 |
|
|
2025
Q1 | $2.93M | Hold |
6,040
| – | – | 0.13% | 88 |
|
|
2024
Q4 | $2.43M | Buy |
6,040
+66
| +1% | +$30.6K | 0.1% | 94 |
|
|
2024
Q3 | $2.78M | Buy |
5,974
+12
| +0.2% | +$5.76K | 0.12% | 90 |
|
|
2024
Q2 | $2.79M | Buy |
5,962
+25
| +0.4% | +$10.9K | 0.13% | 88 |
|
|
2024
Q1 | $2.48M | Hold |
5,937
| – | – | 0.12% | 96 |
|
|
2023
Q4 | $2.42M | Hold |
5,937
| – | – | 0.13% | 95 |
|
|
2023
Q3 | $2.06M | Buy |
5,937
+81
| +1% | +$28.3K | 0.13% | 97 |
|
|
2023
Q2 | $2.06M | Hold |
5,856
| – | – | 0.13% | 101 |
|
|
2023
Q1 | $1.85M | Sell |
5,856
-267
| -4% | -$80.1K | 0.12% | 104 |
|
|
2022
Q4 | $1.77M | Buy |
6,123
+210
| +4% | +$64K | 0.12% | 103 |
|
|
2022
Q3 | $1.71M | Sell |
5,913
-708
| -11% | -$204K | 0.13% | 102 |
|
|
2022
Q2 | $1.87M | Sell |
6,621
-2,530
| -28% | -$677K | 0.13% | 97 |
|
|
2022
Q1 | $2.39M | Buy |
9,151
+479
| +6% | +$114K | 0.14% | 95 |
|
|
2021
Q4 | $1.9M | Sell |
8,672
-465
| -5% | -$90.4K | 0.11% | 97 |
|
|
2021
Q3 | $1.66M | Buy |
9,137
+68
| +0.7% | +$13.3K | 0.11% | 111 |
|
|
2021
Q2 | $1.83M | Buy |
9,069
+53
| +0.6% | +$11.1K | 0.12% | 101 |
|
|
2021
Q1 | $1.94M | Buy |
9,016
+4,572
| +103% | +$1M | 0.15% | 89 |
|
|
2020
Q4 | $1.05M | Sell |
4,444
-255
| -5% | -$58.5K | 0.09% | 134 |
|
|
2020
Q3 | $1.28M | Buy |
4,699
+4
| +0.1% | +$1.1K | 0.12% | 105 |
|
|
2020
Q2 | $1.36M | Buy |
4,695
+649
| +16% | +$176K | 0.13% | 94 |
|
|
2020
Q1 | $963K | Buy |
4,046
+75
| +2% | +$17.2K | 0.11% | 117 |
|
|
2019
Q4 | $869K | Sell |
3,971
-150
| -4% | -$30.4K | 0.08% | 143 |
|
|
2019
Q3 | $698K | Hold |
4,121
| – | – | 0.07% | 158 |
|
|
2019
Q2 | $756K | Hold |
4,121
| – | – | 0.08% | 151 |
|
|
2019
Q1 | $758K | Buy |
+4,121
| New | +$761K | 0.08% | 143 |
|
|
2018
Q3 | – | Sell |
-23,971
| Closed | -$4.07M | – | 173 |
|
|
2018
Q2 | $4.07M | Hold |
23,971
| – | – | 1.26% | 18 |
|
|
2018
Q1 | $3.91M | Sell |
23,971
-39
| -0.2% | -$6.37K | 1.31% | 17 |
|
|
2017
Q4 | $3.6M | Buy |
24,010
+39
| +0.2% | +$5.78K | 1.2% | 21 |
|
|
2017
Q3 | $3.65M | Hold |
23,971
| – | – | 1.34% | 17 |
|
|
2017
Q2 | $3.09M | Hold |
23,971
| – | – | 1.22% | 18 |
|
|
2017
Q1 | $2.62M | Hold |
23,971
| – | – | 1.09% | 18 |
|
|
2016
Q4 | $1.77M | Buy |
23,971
+779
| +3% | +$63.4K | 0.79% | 24 |
|
|
2016
Q3 | $2.02M | Hold |
23,192
| – | – | 0.85% | 25 |
|
|
2016
Q2 | $2M | Sell |
23,192
-193
| -0.8% | -$16.7K | 0.89% | 19 |
|
|
2016
Q1 | $1.86M | Hold |
23,385
| – | – | 0.98% | 22 |
|
|
2015
Q4 | $2.94M | Hold |
23,385
| – | – | 1.53% | 15 |
|
|
2015
Q3 | $2.44M | Hold |
23,385
| – | – | 1.24% | 17 |
|
|
2015
Q2 | $2.89M | Hold |
23,385
| – | – | 1.29% | 14 |
|
|
2015
Q1 | $2.76M | Hold |
23,385
| – | – | 1.26% | 16 |
|
|
2014
Q4 | $2.78M | Hold |
23,385
| – | – | 1.46% | 14 |
|
|
2014
Q3 | $2.63M | Hold |
23,385
| – | – | 1.44% | 15 |
|
|
2014
Q2 | $2.21M | Hold |
23,385
| – | – | 1.25% | 17 |
|
|
2014
Q1 | $1.65M | Buy |
23,385
+3,385
| +17% | +$268K | 0.97% | 22 |
|
|
2013
Q4 | $1.49M | Buy |
+20,000
| New | +$1.39M | 0.99% | 21 |
|
Other funds holding VRTX
Northeast Financial Consultants's VRTX Position: Q2 2025 in Review
Northeast Financial Consultants held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2025 at 6,040 shares worth $2.69M. The position accounts for 0.11% of the portfolio, ranked #90.
Northeast Financial Consultants first reported a position in VRTX in Q4 2013 and has held it in 45 quarters since. The position peaked at $4.07M in Q2 2018. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.
- Northeast Financial Consultants held 6,040 shares of Vertex Pharmaceuticals worth $2.69M as of Q2 2025.
- Northeast Financial Consultants left its Vertex Pharmaceuticals share count unchanged in Q2 2025.
- Vertex Pharmaceuticals made up 0.11% of Northeast Financial Consultants's portfolio in Q2 2025, its #90 holding.
- Northeast Financial Consultants first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 45 quarters since.
- Northeast Financial Consultants's Vertex Pharmaceuticals position peaked at $4.07M in Q2 2018.
- 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.
Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.